References
Abbasi, S., M. Noruzinia, O. Bashti, M. Ahmadvand, A. R. Salehi
Chaleshtori, and L. Mahootipou. 2017. “Another Novel Missense Mutation
in ARSB Gene in Iran.” Acta Medica Iranica 55(9):585–90.
Alaei, Mohammad Reza, Meghdad Kheirkhahan, Saeed Talebi, Elham
Davoudi-Dehaghani, and Mohammad Keramatipour. 2020. “Once in a Blue
Moon, a Very Rare Coexistence of Glutaric Acidemia Type I and
Mucopolysaccharidosis Type IIIB in a Patient.” Iranian Biomedical
Journal 24(3):201–5. doi: 10.29252/ibj.24.3.201.
Alif, N., K. Hess, J. Straczek, S. Sebbar, A. N’Bou, P. Nabet, and B.
Dousset. 1999. “Mucopolysaccharidosis Type I: Characterization of a
Common Mutation That Causes Hurler Syndrome in Moroccan Subjects.”Annals of Human Genetics 63(Pt 1):9–16. doi:
10.1046/j.1469-1809.1999.6310009.x [doi].
Al-Jasmi, F. A., N. Tawfig, A. Berniah, B. R. Ali, M. Taleb, J. L.
Hertecant, F. Bastaki, and A. K. Souid. 2013. “Prevalence and Novel
Mutations of Lysosomal Storage Disorders in United Arab Emirates : LSD
in UAE.” JIMD Reports 10:1–9. doi: 10.1007/8904_2012_182
[doi].
Aminzadeh, M., N. Malekpour, and P. Ghandil. 2019. “Identification of
Arylsulfatase B Gene Mutations and Clinical Presentations of Iranian
Patients with Mucopolysaccharidosis VI.” Gene 706:1–5. doi:
S0378-1119(19)30403-2 [pii].
Atceken, N., R. K. Ozgul, D. Yucel Yilmaz, A. Tokatli, T. Coskun, H. S.
Sivri, A. Dursun, and M. Karaca. 2016. “Evaluation and Identification
of IDUA Gene Mutations in Turkishpatients with Mucopolysaccharidosis
Type I.” Turkish Journal of Medical Sciences 46(2):404–8. doi:
10.3906/sag-1411-160 [doi].
Bertola, F., M. Filocamo, G. Casati, M. Mort, C. Rosano, A.
Tylki-Szymanska, B. Tuysuz, O. Gabrielli, S. Grossi, M. Scarpa, G.
Parenti, D. Antuzzi, J. Dalmau, M. Di Rocco, C. Dionisi Vici, I. Okur,
J. Rosell, A. Rovelli, F. Furlan, M. Rigoldi, A. Biondi, D. N. Cooper,
and R. Parini. 2011. “IDUA Mutational Profiling of a Cohort of 102
European Patients with Mucopolysaccharidosis Type I: Identification and
Characterization of 35 Novel Alpha-L-Iduronidase (IDUA) Alleles.”Human Mutation 32(6):2189. doi: 10.1002/humu.21479 [doi].
Bidchol, A. M., A. Dalal, H. Shah, S. S, S. Nampoothiri, M. Kabra, N.
Gupta, S. Danda, K. Gowrishankar, S. R. Phadke, S. Kapoor, M. Kamate, I.
C. Verma, R. D. Puri, V. H. Sankar, A. R. Devi, S. J. Patil, P.
Ranganath, S. J. Jain, M. Agarwal, A. Singh, P. Mishra, P. M. Tamhankar,
P. M. Gopinath, H. A. Nagarajaram, K. Satyamoorthy, and K. M. Girisha.
2014. “GALNS Mutations in Indian Patients with Mucopolysaccharidosis
IVA.” American Journal of Medical Genetics.Part A164A(11):2793–2801. doi: 10.1002/ajmg.a.36735 [doi].
Brusius-Facchin, A. C., M. Siebert, D. Leao, D. R. Malaga, G. Pasqualim,
F. Trapp, U. Matte, R. Giugliani, and S. Leistner-Segal. 2019.
“Phenotype-Oriented NGS Panels for Mucopolysaccharidoses: Validation
and Potential Use in the Diagnostic Flowchart.” Genetics and
Molecular Biology 42(1 suppl 1):207–14. doi: S1415-47572019000200207
[pii].
Chkioua, L., S. Khedhiri, A. Kassab, A. Bibi, S. Ferchichi, R.
Froissart, C. Vianey-Saban, S. Laradi, and A. Miled. 2011. “Molecular
Analysis of Mucopolysaccharidosis Type I in Tunisia: Identification of
Novel Mutation and Eight Novel Polymorphisms.” Diagnostic
Pathology 6:39–39. doi: 10.1186/1746-1596-6-39 [doi].
Cobos, P. N., C. Steglich, R. Santer, Z. Lukacs, and A. Gal. 2015.
“Dried Blood Spots Allow Targeted Screening to Diagnose
Mucopolysaccharidosis and Mucolipidosis.” JIMD Reports15:123–32. doi: 10.1007/8904_2014_308 [doi].
Consortium, 1000 Genomes Project, G. R. Abecasis, D. Altshuler, A.
Auton, L. D. Brooks, R. M. Durbin, R. A. Gibbs, M. E. Hurles, and G. A.
McVean. 2010. “A Map of Human Genome Variation from Population-Scale
Sequencing.” Nature 467(7319):1061–73. doi: 10.1038/nature09534
[doi].
Costa-Motta, F. M., F. Bender, A. Acosta, K. Abe-Sandes, T. Machado, T.
Bomfim, T. Boa Sorte, D. da Silva, A. Bittles, R. Giugliani, and S.
Leistner-Segal. 2014. “A Community-Based Study of Mucopolysaccharidosis
Type VI in Brazil: The Influence of Founder Effect, Endogamy and
Consanguinity.” Human Heredity 77(1–4):189–96. doi:
10.1159/000358404 [doi].
Eisenberger, T., C. Neuhaus, A. O. Khan, C. Decker, M. N. Preising, C.
Friedburg, A. Bieg, M. Gliem, P. Charbel Issa, F. G. Holz, S. M. Baig,
Y. Hellenbroich, A. Galvez, K. Platzer, B. Wollnik, N. Laddach, S. R.
Ghaffari, M. Rafati, E. Botzenhart, S. Tinschert, D. Borger, A. Bohring,
J. Schreml, S. Kortge-Jung, C. Schell-Apacik, K. Bakur, J. Y. Al-Aama,
T. Neuhann, P. Herkenrath, G. Nurnberg, P. Nurnberg, J. S. Davis, A.
Gal, C. Bergmann, B. Lorenz, and H. J. Bolz. 2013. “Increasing the
Yield in Targeted Next-Generation Sequencing by Implicating CNV
Analysis, Non-Coding Exons and the Overall Variant Load: The Example of
Retinal Dystrophies.” PloS One 8(11):e78496. doi:
10.1371/journal.pone.0078496 [doi].
Filocamo, M., R. Tomanin, F. Bertola, and A. Morrone. 2018.Biochemical and Molecular Analysis in Mucopolysaccharidoses: What
a Paediatrician Must Know . Vol. 44.
Fox, E. J., K. S. Reid-Bayliss, M. J. Emond, and L. A. Loeb. 2014.
“Accuracy of Next Generation Sequencing Platforms.” Next
Generation, Sequencing & Applications 1:10.4172/jngsa.1000106. doi:
1000106 [pii].
Ghaffari, Saeed Reza, and Maryam Rafati. 2020. “Iran Variome MPS
Database.” Retrieved June 26, 2021 (https://variome.ir/lovd).
Harismendy, O., P. C. Ng, R. L. Strausberg, X. Wang, T. B. Stockwell, K.
Y. Beeson, N. J. Schork, S. S. Murray, E. J. Topol, S. Levy, and K. A.
Frazer. 2009. “Evaluation of next Generation Sequencing Platforms for
Population Targeted Sequencing Studies.” Genome Biology10(3):R32-r32. Epub 2009 Mar 27. doi: 10.1186/gb-2009-10-3-r32
[doi].
Jafaryazdi, Rokhsareh, Sedigheh Shams, Anna Isaian, Aria Setoodeh, and
Shahram Teimourian. 2019. “Identification of Eleven Different Mutations
Including Six Novel, in the Arylsulfatase B Gene in Iranian Patients
with Mucopolysaccharidosis Type VI.” Molecular Biology Reports46(3):3417–26. doi: 10.1007/s11033-019-04804-9.
Jafaryazdi, Rokhsareh, Sediqheh Shams, Anna Isaian, Emel Ebadi, Reza
Safaralizadeh, and Shahram Teimourian. 2018. “A Novel Compound
Heterozygote Mutation in the ARSB Gene in a Patient with Maroteaux-Lamy
Syndrome and Its Insilico Evaluation.” Meta Gene 18:127–31.
doi: https://doi.org/10.1016/j.mgene.2018.08.013.
Kadali, S., S. M. Naushad, A. Radha Rama Devi, and V. L. Bodiga. 2019.Biochemical, Machine Learning and Molecular Approaches for the
Differential Diagnosis of Mucopolysaccharidoses . Vol. 458.
Kamranjam, M., and M. Alaei. 2019. “Mutation Analysis of the IDUA Gene
in Iranian Patients with Mucopolysaccharidosis Type 1: Identification of
Four Novel Mutations.” Genetic Testing and Molecular Biomarkers23(8):515–22. doi: 10.1089/gtmb.2019.0022 [doi].
Kantaputra, P. N., H. Kayserili, Y. Guven, W. Kantaputra, M. C. Balci,
P. Tanpaiboon, N. Tananuvat, A. Uttarilli, and A. Dalal. 2014.
“Clinical Manifestations of 17 Patients Affected with
Mucopolysaccharidosis Type VI and Eight Novel ARSB Mutations.”American Journal of Medical Genetics.Part A 164A(6):1443–53.
doi: 10.1002/ajmg.a.36489 [doi].
Khan, S. A., H. Peracha, D. Ballhausen, A. Wiesbauer, M. Rohrbach, M.
Gautschi, R. W. Mason, R. Giugliani, Y. Suzuki, K. E. Orii, T. Orii, and
S. Tomatsu. 2017. “Epidemiology of Mucopolysaccharidoses.”Molecular Genetics and Metabolism 121(3):227–40. doi:
S1096-7192(17)30206-8 [pii].
Khorrami, Mehdi, Manijeh Mahdavi, Fatemeh Fakhr, and Majid Kheirollahi.
2019. “In Silico Analysis of A Novel Pathogenic Variant in an Iranian
Mucopolysaccharidosis IIIB Patient Identified by Targeted
Next-Generation Sequencing.” Iranian Journal of Child Neurology13(4):173–83. doi: 10.22037/ijcn.v13i4.19894.
Laradi, S., T. Tukel, M. Erazo, J. Shabbeer, L. Chkioua, S. Khedhiri, S.
Ferchichi, M. Chaabouni, A. Miled, and R. J. Desnick. 2005.
“Mucopolysaccharidosis I: Alpha-L-Iduronidase Mutations in Three
Tunisian Families.” Journal of Inherited Metabolic Disease28(6):1019–26. doi: 10.1007/s10545-005-0197-4 [doi].
Malekpour, Nasrin, Rahim Vakili, and Tayebeh Hamzehloie. 2018.
“Mutational Analysis of ARSB Gene in Mucopolysaccharidosis Type VI:
Identification of Three Novel Mutations in Iranian Patients.”Iranian Journal of Basic Medical Sciences 21(9):950–56. doi:
10.22038/IJBMS.2018.27742.6760.
Mansour, Salehi, Salehi Rasoul, and Nasr Esfahani B. 2007. “MOLECULAR
DETECTION AND IDENTIFICATION OF ALFA- L-IDURONIDASE GENE MUTATIONSJN 5
IRANIAN FAMILIES SUSPECTED FOR MULLER SYNDROME (MUCOPOLYSACCHARIDOSIS
I).” 15(2):57–63.
Martin, R., M. Beck, C. Eng, R. Giugliani, P. Harmatz, V. Munoz, and J.
Muenzer. 2008. “Recognition and Diagnosis of Mucopolysaccharidosis II
(Hunter Syndrome).” Pediatrics 121(2):377. doi:
10.1542/peds.2007-1350 [doi].
Martins, Carla, Paula Frassinetti V. de Medeiros, Sandra Leistner‐Segal,
Larbi Dridi, Nursel Elcioglu, Jill Wood, Mahdiyeh Behnam, Bilge Noyan,
Lucia Lacerda, Michael T. Geraghty, Damian Labuda, Roberto Giugliani,
and Alexey V. Pshezhetsky. 2019. “Molecular Characterization of a Large
Group of Mucopolysaccharidosis Type IIIC Patients Reveals the
Evolutionary History of the Disease.” Human Mutation40(8):1084–1100. doi: https://doi.org/10.1002/humu.23752.
Montano, A. M., N. Lock-Hock, R. D. Steiner, B. H. Graham, M. Szlago, R.
Greenstein, M. Pineda, A. Gonzalez-Meneses, M. Coker, D. Bartholomew, M.
S. Sands, R. Wang, R. Giugliani, A. Macaya, G. Pastores, A. K. Ketko, F.
Ezgu, A. Tanaka, L. Arash, M. Beck, R. E. Falk, K. Bhattacharya, J.
Franco, K. K. White, G. A. Mitchell, L. Cimbalistiene, M. Holtz, and W.
S. Sly. 2016. “Clinical Course of Sly Syndrome (Mucopolysaccharidosis
Type VII).” Journal of Medical Genetics 53(6):403–18. doi:
10.1136/jmedgenet-2015-103322 [doi].
Morrone, A., A. Caciotti, R. Atwood, K. Davidson, C. Du, P.
Francis-Lyon, P. Harmatz, M. Mealiffe, S. Mooney, T. R. Oron, A. Ryles,
K. A. Zawadzki, and N. Miller. 2014. “Morquio A Syndrome-Associated
Mutations: A Review of Alterations in the GALNS Gene and a New
Locus-Specific Database.” Human Mutation 35(11):1271–79. doi:
10.1002/humu.22635 [doi].
Mosallanejad, A., M. Alaei, S. R. Ghaffari, M. Rafati, and H. Saneifard.
2020. “Non-Progressive Nonimmune Hydrops Fetalis Caused by a Novel
Mutation in GUSB Gene.” Iranian Journal of Child Neurology14(2):101–6. doi: jcn-14-101 [pii].
Muenzer, J., M. Beck, R. Giugliani, Y. Suzuki, A. Tylki-Szymanska, V.
Valayannopoulos, A. Vellodi, and J. E. Wraith. 2011. “Idursulfase
Treatment of Hunter Syndrome in Children Younger than 6 Years: Results
from the Hunter Outcome Survey.” Genetics in Medicine : Official
Journal of the American College of Medical Genetics 13(2):102–9. doi:
10.1097/GIM.0b013e318206786f [doi].
Muenzer, J., J. E. Wraith, L. A. Clarke, International Consensus Panel
on Management, and I. Treatment of Mucopolysaccharidosis. 2009.
“Mucopolysaccharidosis I: Management and Treatment Guidelines.”Pediatrics 123(1):19–29. doi: 10.1542/peds.2008-0416 [doi].
Northover, H., R. A. Cowie, and J. E. Wraith. 1996.
“Mucopolysaccharidosis Type IVA (Morquio Syndrome): A Clinical
Review.” Journal of Inherited Metabolic Disease 19(3):357–65.
doi: 10.1007/BF01799267 [doi].
Nouri, Nayerossadat, Nargesossadat Nouri, Omid Aryani, Behnam
Kamalidehghan, and Massoud Houshmand. 2012. “Identification of a Novel
Arylsulfatase B Gene Mutation in Three Unrelated Iranian
Mucopolysaccharidosis Type-VI Patients with Different Phenotype
Severity.” Iranian Biomedical Journal 16(3):169–71. doi:
10.6091/ibj.1049.2012.
Papadimitriou, Sofia, Andrea Gazzo, Nassim Versbraegen, Charlotte
Nachtegael, Jan Aerts, Yves Moreau, Sonia Van Dooren, Ann Nowé,
Guillaume Smits, and Tom Lenaerts. 2019. “Predicting Disease-Causing
Variant Combinations.” Proceedings of the National Academy of
Sciences of the United States of America 116(24):11878–87. doi:
10.1073/pnas.1815601116.
Quail, M. A., I. Kozarewa, F. Smith, A. Scally, P. J. Stephens, R.
Durbin, H. Swerdlow, and D. J. Turner. 2008. “A Large Genome Center’s
Improvements to the Illumina Sequencing System.” Nature Methods5(12):1005–10. doi: 10.1038/nmeth.1270 [doi].
Regier, Debra S., Matthew Oetgen, and Pranoot Tanpaiboon. 1993.
“Mucopolysaccharidosis Type IVA.” in GeneReviews® , edited by M.
P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. Bean, G.
Mirzaa, and A. Amemiya. Seattle (WA): University of Washington, Seattle.
Salehi, R. 2004. “REPORT OF A NOVEL MUTATION IN Α-L-IDURONIDASE (IDUA)
IN AN IRANIAN FAMILY WITH HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS I).”
17(1):80–88.
Scarpa, M. 1993. “Mucopolysaccharidosis Type II.”GeneReviews((R)) , edited by M. P. Adam, H. H. Ardinger, R. A.
Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, and A. Amemiya.
Seattle (WA): University of Washington, Seattle. GeneReviews is a
registered trademark of the University of Washington, Seattle. All
rights reserved.
Seyedhassani, Seyed Mohammad, Feyzollah Hashemi-Gorji, Mahdieh Yavari,
and Reza Mirfakhraie. 2015. “Novel Missense Mutation in the GALNS Gene
in an Affected Patient with Severe Form of Mucopolysaccharidosis Type
IVA.” Clinica Chimica Acta 450:121–24. doi:
https://doi.org/10.1016/j.cca.2015.08.006.
Shafaat, Seyed Mehdi, Mehrdad Hashemi, Ahmad Majd, Maryam Abiri, and
Sirous Zeinali. 2020. “Genetic Assessment of Mucopolysaccharidosis Type
IV and the First Pathological Mutation of c.313A>G in the
Iranian Population.” The Horizon of Medical Sciences26(2):182–91. doi: 10.32598/hms.26.2.3275.1.
Stenson, Peter D., Matthew Mort, Edward V. Ball, Katy Shaw, Andrew
Phillips, and David N. Cooper. 2014. “The Human Gene Mutation Database:
Building a Comprehensive Mutation Repository for Clinical and Molecular
Genetics, Diagnostic Testing and Personalized Genomic Medicine.”Human Genetics 133(1):1–9. doi: 10.1007/s00439-013-1358-4.
Taghikhani, Mohammad, Shohreh Khatami, Mohammad Abdi, Mohammad Said
Hakhamaneshi, Mohammad Reza Alaei, Daniel Zamanfar, and Rahim Vakili.
2019. “Mutation Analysis and Clinical Characterization of Iranian
Patients with Mucopolysaccharidosis Type I.” Journal of Clinical
Laboratory Analysis 33(8):e22963. doi:
https://doi.org/10.1002/jcla.22963.
Tomanin, R., L. Karageorgos, A. Zanetti, M. Al-Sayed, M. Bailey, N.
Miller, H. Sakuraba, and J. J. Hopwood. 2018. “Mucopolysaccharidosis
Type VI (MPS VI) and Molecular Analysis: Review and Classification of
Published Variants in the ARSB Gene.” Human Mutation39(12):1788–1802. doi: 10.1002/humu.23613 [doi].
Tomatsu, S., M. Filocamo, K. O. Orii, W. S. Sly, M. A. Gutierrez, T.
Nishioka, O. P. Serrato, P. Di Natale, A. M. Montano, S. Yamaguchi, N.
Kondo, T. Orii, and A. Noguchi. 2004. “Mucopolysaccharidosis IVA
(Morquio A): Identification of Novel Common Mutations in the
N-Acetylgalactosamine-6-Sulfate Sulfatase (GALNS) Gene in Italian
Patients.” Human Mutation 24(2):187–88. doi: 10.1002/humu.9265
[doi].
Tomatsu, S., A. M. Montano, H. Oikawa, M. Smith, L. Barrera, Y. Chinen,
M. M. Thacker, W. G. Mackenzie, Y. Suzuki, and T. Orii. 2011.
“Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review
and Current Treatment.” Current Pharmaceutical Biotechnology12(6):931–45. doi: 1389-2010/11 $58.00+.00 [doi].
Valstar, M. J., S. Neijs, H. T. Bruggenwirth, R. Olmer, G. J. Ruijter,
R. A. Wevers, O. P. van Diggelen, B. J. Poorthuis, D. J. Halley, and F.
A. Wijburg. 2010. “Mucopolysaccharidosis Type IIIA: Clinical Spectrum
and Genotype-Phenotype Correlations.” Annals of Neurology68(6):876–87. doi: 10.1002/ana.22092 [doi].
Valstar, Marlies J., Aida Bertoli-Avella, Marja W. Wessels, George J. G.
Ruijter, Bianca de Graaf, Renske Olmer, Peter Elfferich, Sanne Neijs,
Roxana Kariminejad, Fatih Suheyl Ezgü, Aysegul Tokatli, Barbara
Czartoryska, Ad N. Bosschaart, Feikje van den Bos-Terpstra, Hugues
Puissant, Friederike Bürger, Heymut Omran, D. Eckert, Mirella Filocamo,
Emil Simeonov, Patrick J. Willems, Ron A. Wevers, Martinus F.
Niermeijer, Dicky J. J. Halley, Ben J. H. M. Poorthuis, and Otto P. van
Diggelen. 2010. “Mucopolysaccharidosis Type IIID: 12 New Patients and
15 Novel Mutationsb.” Human Mutation 31(5):E1348–60. doi:
https://doi.org/10.1002/humu.21234.
Wang, Z., W. Zhang, Y. Wang, Y. Meng, L. Su, H. Shi, and S. Huang. 2010.
“Mucopolysaccharidosis IVA Mutations in Chinese Patients: 16 Novel
Mutations.” Journal of Human Genetics 55(8):534–40. doi:
10.1038/jhg.2010.65 [doi].
Wood, T. C., K. Harvey, M. Beck, M. G. Burin, Y. H. Chien, H. J. Church,
V. D’Almeida, O. P. van Diggelen, M. Fietz, R. Giugliani, P. Harmatz, S.
M. Hawley, W. L. Hwu, D. Ketteridge, Z. Lukacs, N. Miller, M. Pasquali,
A. Schenone, J. N. Thompson, K. Tylee, C. Yu, and C. J. Hendriksz. 2013.
“Diagnosing Mucopolysaccharidosis IVA.” Journal of Inherited
Metabolic Disease 36(2):293–307. doi: 10.1007/s10545-013-9587-1
[doi].
Yassaee, Vahid Reza, Feyzollah Hashemi-Gorji, Mohammad Miryounesi,
Alireza Rezayi, Zeinab Ravesh, Fakhrolmolouk Yassaee, and Shadab
Salehpour. 2017. “Clinical, Biochemical and Molecular Features of
Iranian Families with Mucopolysaccharidosis: A Case Series.”Clinica Chimica Acta 474:88–95. doi:
https://doi.org/10.1016/j.cca.2017.08.017.